From eye drops for glaucoma to chewing gum for irritable bowel syndrome, derivatives of cannabis are making their way into FDA trials, fueling a biotech/pharma market that could be worth $20 billion by 2020.
Chief among the molecules of interest is cannabidiol or CBD. Like THC, CBD is believed to have a variety of therapeutic benefits. It does not, however, deliver a hallucinogenic high, making it more suitable for children and adults hoping to live a normal life while taking substantial doses.
Below are five biopharma companies pursuing such therapies, each with its own take on drug delivery and treatment for a diverse range of diseases and disorders.
Devon, Pennsylvania-based Zynerba has both a synthetic gel and a patch that can deliver CBD transdermally. In a field
... read more at: https://medcitynews.com/2017/02/five-companies-medicine-marijuana/